Hemostemix Inc (CVE:HEM)’s share price was down 50% on Thursday . The company traded as low as C$0.01 and last traded at C$0.01, approximately 1,471,000 shares were traded during trading. An increase of 1,388% from the average daily volume of 98,865 shares. The stock had previously closed at C$0.02.
The firm has a market cap of $6.02 million and a P/E ratio of -0.50. The stock’s fifty day moving average is C$0.03 and its two-hundred day moving average is C$0.04.
About Hemostemix (CVE:HEM)
Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.
Featured Article: Margin
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.